Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HPGD | P15428 | 2/20 | 0.58 |
| ▸ | LMNA | P02545 | 4/20 | 0.50 |
| ▸ | TSHR | P16473 | 2/20 | 0.50 |
| ▸ | GAA | P10253 | 3/20 | 0.45 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.43 |
| ▸ | ACHE | P22303 | 2/20 | 0.39 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.38 |
| ▸ | MEN1 | O00255 | 4/20 | 0.38 |
| ▸ | KMT2A | Q03164 | 4/20 | 0.38 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.34 |
| ▸ | MAPT | P10636 | 1/20 | 0.34 |
| ▸ | HTT | P42858 | 1/20 | 0.34 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5488946 | 0.80 | HPGD (0.52) | HPGDLMNATSHRGAACYP3A4 | |
| SCHEMBL384926 | 0.78 | HPGD (0.54) | HPGDLMNATSHRGAACYP3A4 | |
| SCHEMBL3895562 | 0.78 | HPGD (0.54) | HPGDLMNATSHRGAACYP3A4 | |
| SCHEMBL780147 | 0.78 | CA2 (0.50) | LMNAACHETDP1MEN1KMT2A | |
| SCHEMBL5482554 | 0.77 | HPGD (0.48) | HPGDLMNATSHRGAACYP3A4 | |
| SCHEMBL10237191 | 0.74 | HPGD (0.50) | HPGDLMNATSHRGAACYP3A4 | |
| SCHEMBL5492110 | 0.74 | HPGD (0.45) | HPGDLMNATSHRGAACYP3A4 | |
| SCHEMBL2209561 | 0.74 | CA1 (0.50) | HPGDTSHRTDP1KMT2AALDH1A1 | |
| SCHEMBL5490568 | 0.74 | ACHE (0.42) | HPGDLMNAACHETDP1MEN1 | |
| SCHEMBL3888438 | 0.74 | HPGD (0.70) | HPGDLMNATSHRGAACYP3A4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 15 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-117043226-A | Polyester compositions comprising tetramethylcyclobutanediol and cyclohexanedimethanol with improved catalyst systems comprising lithium and aluminum atoms | 伊士曼化工公司 | 2023-11-10 | — | — | CN | disclosed |
| CN-109563252-B | Polyester compositions comprising tetramethylcyclobutanediol and ethylene glycol using an improved catalyst system | 伊士曼化工公司 | 2022-04-26 | — | — | CN | disclosed |
| CN-109563247-B | Polyester compositions comprising tetramethylcyclobutanediol and ethylene glycol using an improved catalyst system | 伊士曼化工公司 | 2021-10-08 | — | — | CN | disclosed |
| US-8765722-B2 | Inhibitors of flaviviridae viruses | GILEAD SCIENCES, INC. (US) | 2014-07-01 | — | — | US | disclosed |
| US-8765722-B2 | Inhibitors of flaviviridae viruses | GILEAD SCIENCES, INC. (US) | 2014-07-01 | — | — | US | disclosed |
| US-20130302280-A1 | INHIBITORS OF FLAVIVIRIDAE VIRUSES | GILEAD SCIENCES, INC. | 2013-11-14 | — | — | US | disclosed |
| US-20130302280-A1 | INHIBITORS OF FLAVIVIRIDAE VIRUSES | GILEAD SCIENCES, INC. | 2013-11-14 | — | — | US | disclosed |
| US-8501714-B2 | Inhibitors of Flaviviridae viruses | GILEAD SCIENCES, INC. (US) | 2013-08-06 | — | — | US | disclosed |
| US-20120156166-A1 | INHIBITORS OF FLAVIVIRIDAE VIRUSES | GILEAD SCIENCES, INC. (US) | 2012-06-21 | — | — | US | disclosed |
| US-20120156166-A1 | INHIBITORS OF FLAVIVIRIDAE VIRUSES | GILEAD SCIENCES, INC. (US) | 2012-06-21 | — | — | US | disclosed |
| WO-2011031669-A1 | INHIBITORS OF FLAVIVIRIDAE VIRUSES | GILEAD SCIENCES, INC. (US) | 2011-03-17 | — | — | WO | disclosed |
| US-20070087270-A1 | NONAQUEOUS ELECTROLYTE SOLUTION AND NONAQUEOUS ELECTROLYTE SOLUTION SECONDARY BATTERY EMPLOYING THE SAME | MITSUBISHI CHEMICAL CORPORATION (JP) | 2007-04-19 | — | — | US | disclosed |
| US-7169511-B2 | Nonaqueous electrolyte solution and nonaqueous electrolyte solution secondary battery employing the same | MITSUBISHI CHEMICAL CORPORATION (JP) | 2007-01-30 | — | — | US | disclosed |
| EP-1555711-A1 | NONAQUEOUS ELECTROLYTIC SOLUTION AND NONAQUEOUS ELECTROLYTE SECONDARY BATTERY CONTAINING THE SAME | Mitsubishi Chemical Corporation (JP) | 2005-07-20 | — | — | EP | disclosed |
| US-20050014071-A1 | Nonaqueous electrolyte solution and nonaqueous electrolyte solution secondary battery employing the same | MITSUBISHI CHEMICAL CORPORATION (JP) | 2005-01-20 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130302280-A1 | INHIBITORS OF FLAVIVIRIDAE VIRUSES | HAVCR2, CYP2F1, CYP4F3 | HPGD 2406/4885LMNA 1554/4885TSHR 4286/4885 |
| US-20120156166-A1 | INHIBITORS OF FLAVIVIRIDAE VIRUSES | HAVCR2, CYP2F1, CYP4F3 | HPGD 2406/4885LMNA 1554/4885TSHR 4286/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.